# Ipamorelin Research: Weighing the Published Evidence > Ipamorelin research, appraised study by study — the founding selectivity data, the human half-life, the failed Phase 2 trial, the GHRH-synergy mechanism behind the CJC-1295 pairing, and comparisons to sermorelin and tesamorelin. Founding pharmacology, the human data, the failed trial, and the mechanism behind the popular pairings — appraised, not amplified. ## Before the details The Ipamorelin research record is small enough to read in full and uneven enough that the order matters. At the strong end sits the founding pharmacology: a clean, reproducible demonstration that this peptide releases growth hormone selectively. In the middle sits a single human pharmacokinetic study and a scatter of rodent work on bone and body weight. At the weak end — or rather, the *negative* end — sits the one human efficacy trial, which failed. Around all of it is a mature anti-doping detection literature. This page walks each tier, says how much weight it can bear, and keeps the mechanism (why ipamorelin is paired with growth-hormone-releasing-hormone analogs like CJC-1295) distinct from the marketing. Jargon is glossed as it appears; nothing here is a dose or a recommendation. ## What is ipamorelin peptide? Ipamorelin is a synthetic pentapeptide — a chain of five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — that activates the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on the pituitary's growth-hormone-producing cells [1]. The two D-form amino acids and the non-natural Aib residue at position one make it resistant to the enzymes that would otherwise chew up a peptide, which is why it survives in the bloodstream long enough to act. Structurally it is a stripped-down descendant of an earlier peptide, GHRP-1, with a central dipeptide removed. Its molecular formula is C38H49N9O5 (about 712 daltons). It is wholly synthetic — not a hormone your body makes — but it mimics the action of natural ghrelin at the same receptor. ## The founding finding: potent growth hormone release, without the stress hormones The 1998 characterization is the cornerstone, and it is the most reproducible claim in the field. Ipamorelin released growth hormone potently in rat pituitary cells, anaesthetised rats, and conscious pigs, with a swine ED50 of 2.3 nmol/kg against 3.9 nmol/kg for GHRP-6 [1]. The defining result: even at doses more than 200-fold above its growth-hormone ED50, it did not raise ACTH or cortisol above the GHRH baseline [1]. That selectivity — full growth-hormone effect, minimal stress-hormone and prolactin effect — is what separated it from every earlier peptide in its class and is the one thing about ipamorelin that the evidence supports without qualification. The characterization was acute, not chronic; it tells you what one pulse does, not what months of dosing do. ## The human data: one half-life, one failed trial Human evidence is limited and, for efficacy, negative. A pharmacokinetic study in healthy men (eight per dose, five intravenous infusions from 4.21 to 140.45 nmol/kg) found dose-proportional kinetics, a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a single growth-hormone pulse peaking near 40 minutes [2]. That is essentially the whole human PK story. The efficacy story is one trial, and it failed. In 114 bowel-resection patients given 0.03 mg/kg intravenously twice daily for up to seven days, ipamorelin missed its primary endpoint — time to first tolerated meal of 25.3 hours versus 32.6 hours on placebo (p=0.15) [3]. Treatment-emergent adverse events were comparable between arms (87.5% ipamorelin vs 94.8% placebo), so there was no specific safety alarm in that short window — but there was also no demonstrated benefit, and the clinical program ended there [3]. ## Rodent and recent data: real effects, narrow scope The animal literature carries ipamorelin's more impressive-sounding numbers, and they deserve to be read for exactly what they are. Subcutaneous ipamorelin (18, 90, 450 micrograms/day, split three times daily for 15 days) raised adult-rat longitudinal bone growth from 42 to 52 microns/day at the top dose — with no measurable change in total IGF-1 or bone-turnover markers, pointing to a partly local, growth-hormone-pulse-driven effect rather than a systemic IGF-1 surge [4]. The freshest in-vivo data is a 2024 ferret study: intraperitoneal ipamorelin (1-3 mg/kg) cut cisplatin-induced body-weight loss by roughly 24% in the delayed phase, through a peripheral mechanism, with no anti-emetic effect — unlike a related compound that did reduce nausea centrally [5]. These are well-conducted studies in animals. They do not establish a human benefit, and the appraisal should not pretend otherwise. ## Ipamorelin cjc-1295: why the pairing exists, mechanistically The ipamorelin cjc-1295 combination is the most-searched topic in this space, so it is worth grounding in mechanism rather than forum lore. Ipamorelin and CJC-1295 act on *different* receptors: ipamorelin on the ghrelin receptor, CJC-1295 as an analog of growth-hormone-releasing hormone (GHRH) on the GHRH receptor. The rationale for combining them is genuine pharmacology. In rats, exogenous GHRH and a GHRP given together produced growth-hormone peaks that were *synergistic* — greater than the sum of each given alone [12]. Blocking endogenous GHRH attenuated GHRP-induced growth-hormone release, proving GHRH tone is a prerequisite for full GHRP effect [13]. A GHRH-knockout mouse model confirmed it: a GHRP alone failed to stimulate growth hormone, but GHRH-analog plus GHRP together restored it [14]. In ovine pituitary cells, the combination upregulated growth-hormone mRNA and receptor expression and suppressed the inhibitory somatostatin receptors [15]. The pairing's *mechanistic* logic is solid. What does not exist is a single controlled human trial of the ipamorelin cjc-1295 combination for any outcome — the synergy is established at the bench, not in people. ## Ipamorelin vs sermorelin Ipamorelin vs sermorelin is a comparison of two different drug classes that are often lumped together. Sermorelin is a GHRH analog — it mimics growth-hormone-releasing hormone and acts on the GHRH receptor. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist acting through a separate pathway [1]. Functionally they push growth hormone by different doors, which is exactly why they are combined rather than substituted. The sharpest practical contrast is regulatory: sermorelin once held FDA approval as a finished drug (later withdrawn from the market) and is handled differently under pharmacy-compounding rules, whereas ipamorelin has never been approved as a drug anywhere [3]. On evidence, both lean heavily on mechanism, but sermorelin carries the legacy of an approved-drug history that ipamorelin simply does not have. ## Ipamorelin vs tesamorelin Ipamorelin vs tesamorelin is the starkest evidence mismatch on this page. Tesamorelin is a GHRH analog that *is* FDA-approved — specifically to reduce excess visceral abdominal fat in one defined population — meaning it cleared controlled human efficacy trials for its indication. Ipamorelin, a ghrelin-receptor agonist working through a different mechanism [1], has the opposite record: its one human efficacy trial failed [3]. So while they are sometimes discussed side by side as "growth-hormone peptides," they sit at opposite ends of the evidence spectrum — one with an approved indication backed by trials, the other with a failed trial and no approval. Reading them as interchangeable misrepresents both. --- An evidence-appraisal reading of the Ipamorelin record — the founding selectivity data weighed against the failed Phase 2 trial and the marketing, with the anti-doping detection science laid out plainly; no clinic behind the appraisal and nothing here dosed, dispensed, or sold.